Reduction in CUA MRI Lesions in the First 6 Months after Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Subgroup Analysis

被引：0
|
作者：
De Stefano, Nicola [1 ]
Barkhof, Frederik [2 ,3 ]
Montalban, Xavier [4 ]
Achiron, Anat [5 ]
Derfuss, Tobias [6 ]
Chan, Andrew [7 ]
Hodgkinson, Suzanne [8 ]
Prat, Alexandre [9 ]
Leocani, Letizia [10 ]
Schmierer, Klaus [11 ,12 ]
Sellebjerg, Finn [13 ]
Vermersch, Patrick [14 ]
Wiendl, Heinz [15 ]
Keller, Birgit [16 ]
Roy, Sanjeev [17 ]
机构：
[1] Univ Siena, Dept Neurol & Behav Sci, Siena, Italy
[2] Vrije Univ Amsterdam, Med Ctr, Dept Radiol, Amsterdam, Netherlands
[3] UCL Inst Neurol, London, England
[4] Hosp Univ Vall dHebron, Ctr Esclerosi Multiple Catalunya Cemcat, Dept Neurol Neuroimmunol, Barcelona, Spain
[5] Sheba Acad Med Ctr, Multiple Sclerosis Ctr, Ramat Gan, Israel
[6] Univ Hosp Basel, Dept Neurol, Basel, Switzerland
[7] Univ Bern, Univ Hosp Berne, Bern, Switzerland
[8] Univ New South Wales Med, Ingham Inst Appl Med Res, Kensington, NSW, Australia
[9] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada
[10] Univ Vita Salute San Raffaele, Expt Neurophysiol, INSPE, Milan, Italy
[11] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[12] Royal London Hosp, Barts Hlth NHS Trust, Clin Board Med Neurosci, London, England
[13] Copenhagen Univ Hosp, Rigshosp, Dept Neurol, Danish MS Ctr, Copenhagen, Denmark
[14] Univ Lille, CHU Lille, INSERM, U1172,LilNCog,FHU Imminent, Lille, France
[15] Univ Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany
[16] Merck KGaA, Darmstadt, Germany
[17] Merck, Aubonne, Switzerland
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1921
引用
收藏
页数：6
相关论文
共 33 条
  • [21] Stabilization of Cognitive Function in Patients With Highly Active Relapsing Multiple Sclerosis Treated With Cladribine Tablets During the 2-Year CLARIFY-MS study
    Langdon, D.
    Brochet, B.
    Havrdova, E. K.
    Lechner-Scott, J.
    Montalban, X.
    Patti, F.
    Piehl, F.
    Selmaj, K.
    Solari, A.
    Alexandri, N.
    Nolting, A.
    Lehn, A.
    Smyk, A.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 60 - 61
  • [22] The Real-World Efficacy of Cladribine Tablets and Treatment Persistence in People with Highly Active Relapsing Multiple Sclerosis in Finland - A Follow-up Study After Four Years of Observation
    Rauma, Ilkka
    Viitala, Matias
    Soilu-Hanninen, Merja
    Atula, Sari
    Laakso, Sini
    Kuusisto, Hanna
    Niiranen, Marja
    Ryytty, Mervi
    Manni, Visa
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 386 - 387
  • [23] EFFICACY OF CLADRIBINE TABLETS IN PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS: ANALYSIS OF POOLED DOUBLE-BLIND DATA FROM THE CLARITY AND ONWARD STUDIES
    Giovannoni, Gavin
    Montalban, Xavier
    Rammohan, Kottil
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Dangond, Fernando
    King, John
    Damian, Doris
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (06): : E27 - E28
  • [24] New MRI lesions and topography at 6 months of treatment initiation and disease activity during follow up in relapsing remitting multiple sclerosis patients
    Silveira, Facundo
    Sanchez, Francisco
    Migueza, Jimena
    Contartese, Laura
    Gomez, Alejandra
    Patrucco, Liliana
    Cristiano, Edgardo
    Ignacio Rojas, Juan
    NEUROLOGICAL RESEARCH, 2020, 42 (02) : 148 - 152
  • [25] Efficacy of cladribine tablets 3.5 mg/kg in patients with highly active relapsing multiple sclerosis (RMS): Pooled analysis of the double-blind cohort from CLARITY and ONWARD
    Giovannoni, G.
    Montalban, X.
    Damian, D.
    Dangond, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 332 - 332
  • [26] Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study
    Selmaj, Krzysztof
    Langdon, Dawn
    Brochet, Bruno
    Solari, Alessandra
    Havrdova, Eva Kubala
    Patti, Francesco
    Piehl, Fredrik
    Smyk, Andrzej
    Lehn, Annette
    Nolting, Axel
    Montalban, Xavier
    Lechner-Scott, Jeannette
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 655 - 657
  • [27] Slowing of Disability Progression Based on 6-Month Confirmed EDSS in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets in the CLARITY Study: A Post-Hoc Subgroup Analysis
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Soelberg-Sorensenn, Per
    Vermersch, Patrick
    Hicking, Christine
    Dangond, Fernando
    Ciovannoni, Gavin
    NEUROLOGY, 2016, 86
  • [28] Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study
    Borriello, Giovanna
    Chisari, Clara Grazia
    Maimone, Davide
    Mirabella, Massimiliano
    Paolicelli, Damiano
    Assogna, Francesco
    Caradonna, Sandro
    Patti, Francesco
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [29] Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I study
    Arnold, D. L.
    Barnett, M.
    Comi, G.
    Giovannoni, G.
    Pelletier, D.
    Rovira, A.
    Schippling, S.
    Van Wijmeersch, B.
    Margolin, D. H.
    Thangavelu, K.
    Traboulsee, A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 329 - 329
  • [30] Cladribine Tablets in Patients With Relapsing-Remitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis After Suboptimal Response to a Disease-Modifying Therapy (CLICK-MS and MASTER-2): Interim Baseline and Safety Review (P1-1.Virtual)
    Miravalle, Augusto A.
    Katz, Joshua
    Robertson, Derrick
    Aldridge, Julie
    Evans, Emily
    Harlow, Danielle E.
    Lebson, Lori A.
    Sloane, Jacob A.
    Bass, Ann D.
    Fox, Edward J.
    NEUROLOGY, 2022, 98 (18)
1234